Edwards Lifesciences (EW) Revenue — Quarter Ended Mar 31, 2026
Revenue for the quarter rose compared to both the preceding quarter and the same period one year earlier. The growth rate versus the prior year was notably higher than the sequential increase.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue for the quarter rose compared to both the preceding quarter and the same period one year earlier. The growth rate versus the prior year was notably higher than the sequential increase.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.6B
Revenue reported for this quarter.
Quarter-over-quarter
+5.0%
Change from the immediately preceding quarter.
Year-over-year
+16.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$6.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $1.5B | +11.9% |
| Sep 30, 2025 | $1.6B | +14.7% |
| Dec 31, 2025 | $1.6B | +13.3% |
| Mar 31, 2026 | $1.6B | +16.7% |
Revenue performance
The reported revenue improved from the immediately preceding quarter, continuing the upward trend seen in recent periods.
Quarterly comparison
Compared to the same quarter last year, revenue registered a strong increase. The sequential quarter-over-quarter rise was more moderate but still positive.
What to watch
Monitor whether the sequential growth rate sustains or accelerates in the coming quarters.